InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: None

Saturday, 01/22/2022 6:40:17 AM

Saturday, January 22, 2022 6:40:17 AM

Post# of 4160
$TLTFF-FULLY FUNDED -The Company successfully completed an oversubscribed marketed public offering on August 22, 2019, raising gross proceeds of CAD $17,250,000, fully funded for Phase II NMIBC Clinical Study.

Analyst Coverage Mackie Research Capital Echelon Wealth Partners Target Price “$0.80” by Mackie Research “$0.50” by Echelon Wealth


TREATMENT FOR VARIOUS CANCERS Planning on initiating Phase 1b study for other cancer indications. Strong upside for growth and valuation.


PowerPoint Presentation Sept 2021

JMO, maybe, maybe not.